



WHAT IS CLAIMED IS:


1. A bicyclic aromatic compound having the structural formula (I) :




in which R_1 is (i) the radical $-CH_3$, (ii) a radical
5 $-CH_2OR_2$; or (iii) a radical $-CO-R_3$, wherein R_2 and R_3 are
as defined below; Ar_1 is a radical selected from among
those of the following formulae (a)-(c) :



(a)








(b)






(c)

wherein R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are as defined
below; Ar_2 is a radical selected from among those of the
10 following formulae (d)-(h) :



wherein R₁₂ and R₁₃ are as defined below; X is a radical selected from among those of the following formulae

(i) - (l) :




(i)

(j)

(k)

(l)

wherein R₁₄, R₁₅ and Y are as defined below; R₂ is a
5 hydrogen atom, a lower alkyl radical or a radical
-CO-R₁₆, wherein R₁₆ is as defined below; R₃ is a
hydrogen atom, a lower alkyl radical, a radical of the
formula:



wherein R' and R" are as defined below, or a radical -OR₁₇, wherein R₁₇ is as defined below; R₄ is a hydrogen atom, a polyether radical, a lower alkyl radical, or a radical -OR₁₈, wherein R₁₈ is as defined below; R₅ is a 5 hydrogen atom, a lower alkyl radical, a polyether radical, or a radical -OR₁₉, wherein R₁₉ is as defined below; R₆ is a tert-butyl radical; R₇ is a lower alkyl radical, a polyether radical, or a radical -OR₂₀, wherein R₂₀ is as defined below, with the proviso that R₆ 10 and R₇ may together form, with the carbon atoms from which they depend, a 6-membered ring optionally substituted with at least one methyl group and/or optionally interrupted by an oxygen or sulfur atom; R₈ is a tert-butyl, adamantyl, aryl or aralkyl radical; R₉ 15 and R₁₀ together form, with the carbon atoms from which they depend, a 5- or 6-membered ring optionally substituted with at least one methyl group and/or optionally interrupted by an oxygen or sulfur atom; R₁₁ is a hydrogen atom, a lower alkyl radical having from 1 20 to 9 carbon atoms, a hydroxyl radical, an alkoxy radical, a polyether radical or a radical -OR₂₁, wherein R₂₁ is as defined below; R₁₂ is a hydrogen atom, a hydroxyl radical, an alkoxy radical, a polyether radical or a radical -OR₂₂, wherein R₂₂ is as defined below; R₁₃ 25 is a hydrogen atom, a lower alkyl radical, or a radical -COR₂₃, wherein R₂₃ is as defined below; R₁₄ and R₁₅, which may be identical or different, are each a hydrogen

atom, or a lower alkyl radical; Y is an oxygen atom or a CH₂ radical; R₁₆ is a lower alkyl radical; R₁₇ is a hydrogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms, an alkenyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl or aralkyl radical or a sugar residue; R' and R", which may be identical or different, are each a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl radical or an amino acid residue, with the proviso that R' and R" may together form, with the nitrogen atom from which they depend, a nitrogenous heterocycle; R₁₈, R₁₉ and R₂₀, which may be identical or different, are each a hydrogen atom, a lower alkyl radical, an alkenyl radical, a mono- or polyhydroxyalkyl radical, an aryl radical, an optionally substituted aralkyl radical or a radical -(CH₂)_n-R₂₄, wherein n and R₂₄ are as defined below; R₂₁ and R₂₂, which may be identical or different, are each an alkenyl radical, a mono- or polyhydroxyalkyl radical, an aryl radical, an optionally substituted aralkyl radical, or a radical -(CH₂)_n-R₂₄, wherein n and R₂₄ are as defined below; R₂₃ is a lower alkyl radical; R₂₄ is a heterocycle, a monohydroxyalkyl radical, a thiol radical optionally substituted with a lower alkyl radical, an amino radical optionally substituted with at least one lower alkyl radical, a radical -COOR₂₅, or a radical -CON(R₂₆)R₂₇, wherein R₂₅, R₂₆ and R₂₇ are as defined below; R₂₅ is a hydrogen atom or a lower alkyl radical;

R₂₆ and R₂₇, which may be identical or different, are each a hydrogen atom, a lower alkyl radical, or an optionally substituted aryl radical, with the proviso that R₂₆ and R₂₇ may together form, with the nitrogen 5 atom from which they depend, a nitrogenous heterocycle; n is an integer such that 2 ≤ n ≤ 9; with the further provisos that, when Ar₁ is the radical of formula (c) and X is a radical of formulae (i) or (j), then R₁₁ is a radical -OR₂₁ or a polyether radical, or when Ar₂ is the 10 radical of formula (d), then R₁₂ is a radical -OR₂₂ or a polyether radical, and the compounds of formula (I) do not include those wherein R₁₁ is a methoxymethoxy radical in an ortho position relative to the substituent Ar₂ when Ar₁ is the radical of formula (c), X is the 15 radical of formula (i), R₁₂ is hydrogen and R₁ is a radical -COR₃ wherein R₃ is a radical -OR₁₇ and R₁₇ is a hydrogen atom, and those wherein R₁₂ is a methoxymethoxy radical in an ortho- or para-position relative to the substituent Ar₁ when Ar₁ is the radical of formula (c), 20 X is the radical of formula (i), R₁₁ is a methyl radical in an ortho-position relative to Ar₂, and R₁ is a radical -COR₃ wherein R₃ is a radical -OR₁₇ and R₁₇ is a hydrogen atom; and the pharmaceutically/cosmetically acceptable optical and geometric isomers and salts 25 thereof.

2. A bicyclic aromatic compound as defined by
Claim 1, wherein formula (I), Ar₁ is a radical having
the formula (a).

3. A bicyclic aromatic compound as defined by
5 Claim 1, wherein formula (I), Ar₁ is a radical having
the formula (b).

4. A bicyclic aromatic compound as defined by
Claim 1, wherein formula (I), Ar₁ is a radical having
the formula (c).

10 5. A bicyclic aromatic compound as defined by any
of Claims 2-4, wherein formula (I), Ar₂ is a radical
having the formula (d).

6. A bicyclic aromatic compound as defined by any
of Claims 2-4, wherein formula (I), Ar₂ is a radical
15 having the formula (e).

7. A bicyclic aromatic compound as defined by any
of Claims 2-4, wherein formula (I), Ar₂ is a radical
having the formula (f).

8. A bicyclic aromatic compound as defined by any
20 of Claims 2-4, wherein formula (I), Ar₂ is a radical
having the formula (g).

9. A bicyclic aromatic compound as defined by any of Claims 2-4, wherein formula (I), Ar₂ is a radical having the formula (h).

10. A bicyclic aromatic compound as defined by
5 Claim 5, wherein formula (I), X is a radical (i).

11. A bicyclic aromatic compound as defined by
Claim 6, wherein formula (I), X is a radical (j).

12. A bicyclic aromatic compound as defined by
Claim 7, wherein formula (I), X is a radical (k).

10 13. A bicyclic aromatic compound as defined by
Claim 8, wherein formula (I), X is a radical (l).

14. A bicyclic aromatic compound as defined by
Claim 1, comprising a pharmaceutically/cosmetically acceptable salt thereof.

15 15. A bicyclic aromatic compound as defined by
Claim 1, wherein formula (I), R₁ is a radical -CO-R₃; Ar₁ is a radical of formulae (d) or (e); R₁₁ is a radical -O-R₂₁; and R₇ is a radical -O-R₂₀.

20 16. A bicyclic aromatic compound as defined by
Claim 1, selected from among

- 3-(3',5'-di-tert-butyl-2'-methoxy-3-biphenyl)acrylic
acid; 3-(2'-benzyloxy-3',5'-di-tert-butyl-6-hydroxy-3'-
biphenyl)acrylic acid; 3-(3',5'-di-tert-butyl-6-
hydroxy-2'-pentyloxy-3-biphenyl)acrylic acid; 3-
(3',5'-di-tert-butyl-6-hydroxy-2'-methoxy-3'-
biphenyl)acrylic acid; 3-[3-(3-benzyloxy-5,5,8,8'-
tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-
methoxymethoxyphenyl]acrylic acid; 3-[3-(3-benzyloxy-
5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-
(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-
naphthyl)phenyl]propynoic acid; [4-methoxymethoxy-3'-
5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-
methoxymethoxyphenyl]acrylic acid; 3-[3-(3-propyloxy-
naphthyl)phenyl]propynoic acid; 3-[3-(3-pentyloxy-
4'-methoxy-2'-methyl-3-biphenyl)acrylic acid; 3-[3-(3-pentyloxy-
adamantan-1-yl-6-hydroxy-4'-methoxy-2'-methyl-3'-
biphenyl)acrylic acid; 3-(5'-adamantan-1-yl-4'-
methoxy-6-methoxymethoxy-2'-methyl-3-biphenyl)acrylic
acid; 3-{4-methoxy-3-[3-(3-methoxybenzyloxy)-5,5,8,8'-
tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]phenyl}acrylic
acid; 3-{4-methoxy-3-[3-(4-methoxybenzyloxy)-5,5,8,8'-
tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]phenyl}acrylic
acid; 3-{3-[3-(6-hydroxyhexyloxy)-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-2-naphthyl]-4-methoxypheyl}acrylic
acid; 3-{3-[3-(7-hydroxyheptyloxy)-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-2-naphthyl]-4-methoxypheyl}acrylic

acid; 3-{3-[3-(5-hydroxypentyloxy)-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic
acid; 3-{3-[3-(3-hydroxypropyloxy)-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic
5 acid; 3-[3-(1-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthyl)phenyl]acrylic acid; 3-(3'-
adamantan-1-yl-4'-hydroxy-3-biphenyl)acrylic acid; 5-[4-
[4-methoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-
naphthyl)phenyl]-3-methylpenta-2,4-dienoic acid; 5-[4-
10 methoxymethoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthyl)phenyl]-3-methylpenta-2,4-dienoic
acid; 5-[4-hydroxy-3-(5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthyl)phenyl]-3-methylpenta-2,4-dienoic
acid; 3-{3-[3-(5-tert-butoxycarbonylpentyloxy)-5,5,8,8-
15 tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-4-
methoxyphenyl}acrylic acid; 3-{3-[3-(7-tert-
butoxycarbonylheptyloxy)-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-
{3-[3-(7-carboxyheptyloxy)-5,5,8,8-tetramethyl-5,6,7,8-
20 tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-
{3-[3-(5-carboxypentyloxy)-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-
{3-[3-(5-carbamoylpentyloxy)-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic
acid; 3-{3-[3-(7-carbamoylheptyloxy)-5,5,8,8-
25 tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-4-
methoxyphenyl}acrylic acid; 3-{4-methoxy-3-[5,5,8,8-
tetramethyl-3-(2-morpholin-4-ylethoxy)-5,6,7,8-

tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-methoxy-
3-[5,5,8,8-tetramethyl-3-(2-piperidin-1-yloxy)-
5,6,7,8-tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-
methoxy-3-[3-(2-methoxymethoxybenzyloxy)-5,5,8,8-
5 tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]phenyl}acrylic
acid; 3-{4-methoxy-3-[3-(3-methoxymethoxybenzyloxy)-
5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-
naphthyl]phenyl}acrylic acid; 3-{4-methoxy-3-[3-(4-
methoxymethoxybenzyloxy)-5,5,8,8-tetramethyl-5,6,7,8-
10 tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-methoxy-
3-[3-(3-hydroxybenzyloxy)-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-[4-fluoro-
3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-
naphthyl)phenyl]acrylic acid; 3-{4-hydroxy-3-[3-(3-
15 methoxybenzyloxy)-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-hydroxy-
3-[3-(4-methoxybenzyloxy)-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-hydroxy-
3-[3-(4-fluorobenzyloxy)-5,5,8,8-tetramethyl-5,6,7,8-
20 tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-hydroxy-
3-[3-(4-chlorobenzyloxy)-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-[4-hydroxy-
3-(3-methoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthyl)phenyl]acrylic acid; 3-(3',5'-di-
25 tert-butyl-6-hydroxy-2'-propyloxy-3-biphenyl)acrylic
acid; 3-(3',5'-di-tert-butyl-6-hydroxy-2'-butyloxy-3-
biphenyl)acrylic acid; 3-(2'-butoxy-3',5'-di-tert-
butyl-6-methoxy-3-biphenyl)acrylic acid; 3-(3'5'-di-

tert-butyl-6-methoxy-2'-propoxy-3-biphenylyl)acrylic acid; 3-[4-hydroxy-3-(5,5,8,8-tetramethyl-4-propoxy-5,6,7,8-tetrahydro-2-naphthyl)phenyl]acrylic acid; 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]acrylic acid; ethyl 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]acrylate; 3-methyl-5-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]penta-2,4-dienoic acid; 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]prop-2-en-1-ol; 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]propenal; N-ethyl 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]acrylamide; 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]-1-morpholin-4-yl-propenone; N-(4-hydroxyphenyl)-3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]acrylamide; 5-(5'-adamantan-1-yl-4'-methoxy-2'methyl-3-biphenylyl)-3-methylpenta-2,4-dienoic acid; 5-[4-methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]-3-methylpenta-2,4-dienoic acid; 5-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]-3-methylpenta-2,4-dienoic acid; 5-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]-3-methylpenta-2,4-dienoic acid; 5-(3',5'-di-tert-butyl-2'-methoxy-3-biphenylyl)-3-

methylpenta-2,4-dienoic acid; 5-(3',5'-di-tert-butyl-2'-propoxy-3-biphenylyl)-3-methylpenta-2,4-dienoic acid; 5-(2'-butoxy-3',5'-di-tert-butyl-3-biphenylyl)-3-methylpenta-2,4-dienoic acid; 5-(2'-butoxy-3',5'-di-tert-butyl-6-hydroxy-3-biphenylyl)-3-methylpenta-2,4-dienoic acid; 5-(3',5'-di-tert-butyl-6-hydroxy-2'-methoxy-3-biphenylyl)-3-methylpenta-2,4-dienoic acid.

10 17. A bicyclic aromatic compound as defined by
Claim 1, having the formula (I) and containing at least
one lower alkyl radical substituent selected from among
methyl, ethyl, isopropyl, butyl, tert-butyl and hexyl
radicals.

15 18. A bicyclic aromatic compound as defined by
Claim 1, having the formula (I) and containing at least
one monohydroxyalkyl radical substituent selected from
among 2-hydroxyethyl, 2-hydroxypropyl and 3-
hydroxypropyl radicals.

20 19. A bicyclic aromatic compound as defined by
Claim 1, having the formula (I) and containing at least
one polyhydroxyalkyl radical substituent selected from
among 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl,
2,3,4,5-tetrahydroxypentyl and pentaerythritol radicals.

20. A bicyclic aromatic compound as defined by
Claim 1, having the formula (I) and containing at least
one aryl radical substituent selected from among phenyl
radicals optionally substituted by at least one halogen
5 atom, or at least one lower alkyl, alkoxy, polyether,
optionally protected amino, hydroxyl or nitro group.

21. A bicyclic aromatic compound as defined by
Claim 1, having the formula (I) and containing at least
one aralkyl radical substituent selected from among
10 benzyl and phenethyl radicals optionally substituted by
at least one halogen atom, or at least one lower alkyl,
alkoxy, polyether, optionally protected amino, hydroxyl
or nitro group.

22. A bicyclic aromatic compound as defined by
15 Claim 1, having the formula (I) and containing at least
one sugar residue substituent selected from among those
of glucose, galactose, mannose and glucuronic acid.

23. A bicyclic aromatic compound as defined by
Claim 1, having the formula (I) and containing at least
20 one amino acid residue substituent selected from among
those of lysine, glycine and aspartic acid.

24. A bicyclic aromatic compound as defined by
Claim 1, having the formula (I) and containing at least
one heterocyclic radical substituent selected from among

piperidino, morpholino, pyrrolidino and piperazino radicals which are optionally substituted by a C₁-C₆ alkyl radical or a mono- or polyhydroxyalkyl radical.

25. A bicyclic aromatic compound as defined by
5 Claim 1, having the formula (I) and containing at least one alkenyl radical substituent having from 2 to 5 carbon atoms and one or more sites of ethylenic unsaturation.

26. A bicyclic aromatic compound as defined by
10 Claim 1, having the formula (I) and containing at least one polyether radical substituent selected from among methoxymethyl ether, methoxyethoxymethyl ether and methylthiomethyl ether radicals.

27. A pharmaceutical composition of matter,
15 comprising a therapeutically effective amount of a bicyclic aromatic compound as defined by Claim 1, or pharmaceutically acceptable salt or isomer thereof, and a pharmaceutically acceptable carrier, diluent or vehicle therefor.

20 28. The pharmaceutical composition as defined by Claim 27, further comprising a retinoid compound, a D vitamin or derivative thereof, a corticosteriod, an anti-free radical agent, an antioxidant, an α -hydroxy or

α -keto acid or derivative thereof, an ion channel blocker, or combination thereof.

29. The pharmaceutical composition as defined by
Claim 27, comprising a tablet, a capsule, a syrup, a
5 suspension, an elixir, a solution, a powder, granules,
an emulsion, microspheres, nanospheres, lipid vesicles,
polymeric vesicles, or an injectable.

30. The pharmaceutical composition as defined by
Claim 27, comprising an ointment, a cream, a milk, a
10 pommade, a salve, an impregnated pad, a gel, a spray, or
a lotion.

31. The pharmaceutical composition as defined by
Claim 27, adopted for topical administration.

32. The pharmaceutical composition as defined by
15 Claim 27, adopted for systemic administration.

33. The pharmaceutical composition as defined by
Claim 27, comprising from 0.001% to 5% by weight of said
bicyclic aromatic compound, or salt or isomer thereof.

34. A regime/regimen for treating a keratinization
20 disorder in a mammalian organism in need of such
treatment, comprising administering to such organism a

therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

35. A regime/regimen for treating a dermatological disorder in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

36. A regime/regimen for treating an ophthalmological disorder in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined in Claim 27.

37. A regime/regimen for treating skin aging in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined in Claim 27.

38. A regime/regimen for treating epidermal and/or dermal atrophy in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

39. A regime/regimen for treating a cicatrization disorder in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined in Claim 27.

5 40. A regime/regimen for treating a sebaceous function disorder in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

10 41. A regime/regimen for treating a cancerous or precancerous disease state in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

15 42. A regime/regimen for treating inflammation in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

20 43. A regime/regimen for treating a viral infection in a mammalian organism in need of such treatment, comprising administering to such organism a

therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

44. A regime/regimen for treating or preventing alopecia in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

45. A regime/regimen for treating a cardiovascular disorder in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

46. A regime/regimen for treating an immune deficiency in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

47. A regime/regimen for treating a dermatological, rheumatic, respiratory, cardiovascular or ophthalmologic disorder in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

48. A regime/regimen as defined by Claim 47, comprising administering to such organism a daily dose of said bicyclic aromatic compound of about 0.01 mg/kg to 100 mg/kg of body weight thereof.

5 49. A cosmetic composition of matter, comprising a cosmetically effective amount of a bicyclic aromatic compound as defined by Claim 1, or cosmetically acceptable salt or isomer thereof, and a cosmetically acceptable carrier, diluent or vehicle therefor.

10 50. The cosmetic composition as defined by Claim 47, comprising a cream, a milk, a lotion, a gel, microspheres, nanospheres, lipid vesicles, polymeric vesicles, a soap, or a shampoo.

15 51. The cosmetic composition as defined by Claim 49, comprising from 0.001% to 3% by weight of said bicyclic aromatic compound, or salt or isomer thereof.

20 52. The cosmetic composition as defined by Claim 49, further comprising a retinoid compound, a D vitamin or derivative thereof, a corticosteroid, an anti-free radical agent, an antioxidant, an α -hydroxy, or α -keto acid or derivative thereof, an ion channel blocker, or combination thereof.

53. A regime/regimen for treating a skin or hair disorder on a mammalian organism in need of such treatment, comprising administering to such organism a cosmetically/therapeutically effective amount of the
5 cosmetic composition as defined by Claim 49.

54. The pharmaceutical composition as defined by Claim 27, further comprising a wetting agent, a depigmenting agent, a moisturizing agent, an antiseborrhoeic or antiacne agent, an antibiotic, an
10 antifungal agent, a hair regrowth promoter, a non-steroidal anti-inflammatory agent, a carotenoid, an anti-psoriatic agent, 5,8,11,14-eicosatetraynoic or 5,8,11-eicosatrynoic acid or ester or amide thereof, or combination thereof.

15 55. The pharmaceutical composition as defined by Claim 27, further comprising a taste- or flavor-enhancing agent, a preservative, a stabilizer, a moisture regulating agent, a pH regulating agent, an osmotic pressure modifying agent, an emulsifying agent,
20 a UV-A or UV-B screening agent, an antioxidant, or combination thereof.

56. The cosmetic composition by Claim 49, further comprising a wetting agent, a depigmenting agent, a moisturizing agent, an antiseborrhoic or antiacne agent,
25 an antibiotic, an antifungal agent, a hair regrowth

promoter, a non-steroidal anti-inflammatory agent, a carotenoid, an anti-psoriatic agent, 5,8,11,14-eicosatetraynoic or 5,8,11-eicosatrynoic acid or ester or amide thereof, or combination thereof.

5 57. The cosmetic composition as defined by Claim
49, further comprising a taste- or flavor-enhancing
agent, a preservative, a stabilizer, a moisture
regulating agent, a pH regulating agent, an osmotic
pressure modifying agent, an emulsifying agent, a UV-A
10 or UV-B screening agent, an antioxidant, or combination
thereof.